Lowest Price Guaranteed
Slides
141
Last Updated
May 2026
View Count
12246
The NAMPT inhibitor developed during our research can be used to target inflammatory disorders, metabolic disorders and oncological disorders. Importantly, our compound has been studied in the preclinical stages, for the treatment of pancreatic cancer
-- Former Research Associate, an India-based mid-sized company
The global NAMPT inhibitor market size is estimated to be worth USD 0.2 billion in 2027 and is anticipated to reach USD 1.3 billion by 2040 at a CAGR of 15% during the forecast period.The high prevalence of cancer, a disease that has the highest mortality rate, has significantly boosted medical research for effective cancer treatment. According to the American Cancer Society, in 2022, 9.7 million people died from the cancer disease globally, and 35 million new cases of cancer are predicted to be diagnosed by 2050.
 |
To learn more about this report, request a free sample copy
In addition to this, as per the National Center for Health Statistics, in 2023, 1 million new cancer cases and more than half of the million cancer deaths were estimated to happen in the United States alone.In this circumstance, the mounting growth of cancer cases worldwide has generated the opportunity for research in the oncology field for effective cancer treatment. In many studies, it is found that the NAMPT inhibitor can be an effective treatment for various types of cancer.
 |
 |
 |
NAMPT inhibitor (Nicotinamide phosphoribosyltransferase) is an enzyme entangled in the biosynthesis of nicotinamide adenine dinucleotide (NAD) a co-enzyme involved in several cellular processes, has the therapeutic potential which makes it a promising target for anti-cancer drugs, by disrupting the energy metabolism of cancer cells and causing death.
The market for NAMPT inhibitors is anticipated to witness remarkable growth due to several driving factors. Majorly, the growing research and development efforts in the field of oncology and metabolic disorders substantially contribute to the discovery of new NAMPT inhibitors with enhanced efficacy and safety profiles. Besides, promising clinical data, rising public and private funding, and growing clinical trials combined with regulatory approvals are further anticipated to accelerate the NAMPT inhibitor market growth over this forecast period. Also, pharmaceutical & biotechnology companies’ emphasis on innovation, high investment in R&D, advancement in drug development, and easy access to these therapies for patients, influence the market growth. However, the efficacy challenges of these drugs and competition from existing therapies could limit the market growth.
The market research report presents an in-depth analysis of the various companies that are engaged in the development of NAMPT inhibitors, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2018 | |
| Forecast Period | Till 2040 | |
| Market Size in 2027 | USD 0.2 Billion | |
| Market Size in 2040 | USD 1.3 Billion | |
| CAGR | 15% | |
| Type Of Molecule |
|
|
| Type of Therapeutic Area |
|
|
| Type of Indication |
|
|
| Type of Route of Administration |
|
|
| Type of Line of Treatment |
|
|
| Key Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
One of the key objectives of this NAMPT inhibitor market report was to estimate the current market size, opportunity, and future growth potential, over the forecast period. Based on multiple parameters, likely adoption trends, and through primary validations, we have provided an informed estimate of the market evolution during the forecast period till 2040. The market report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of molecule (small molecules and biologics), type of therapeutic area (oncological and respiratory disorders), type of indication (non-Hodgkin lymphoma, Hodgkin lymphoma, acute respiratory distress syndrome, and acute myeloid leukemia), type of route of administration (oral and intravenous), type of line of treatment (1st line and 2nd line), and key geographical regions (North America, Europe and Asia Pacific, Latin America, Middle East, North Africa and rest of the world).
In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Based on the type of molecule, the market is split into Small Molecules and Biologics. Small molecules hold 94% of the total NAMPT inhibitor market share and are projected to accelerate the market growth at a CAGR of 15% till 2040. Owing to the oral bioavailability, cell permeability, and established track record in drug development of small molecules, the segment is likely to remain a key driver of NAMPT inhibitors market growth during the forecast period.
Based on the type of therapeutic area, the global NAMPT inhibitor market is categorized into Oncological and Respiratory Disorders. As per market research, oncology diseases dominate the market with 94% of share and are estimated to boost the market growth at 15% CAGR till 2040. The mounting number of cancer cases and growing demand for effective treatment are the key drivers for market growth over this projection timeframe.
Based on the type of indication, the global NAMPT inhibitor market is bifurcated into Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Respiratory Distress Syndrome, and Acute Myeloid Leukemia. According to our analysis, the non-Hodgkin lymphoma segment is likely to hold the largest market share and is expected to escalate the growth of the market due to the growing prevalence of non-Hodgkin lymphoma around the world.
On the basis of route of administration, the market is divided into Oral and Intravenous. As per our projection, the intravenous segment accounts for the largest NAMPT inhibitor market share and is projected to be the leading segment for the growth of the market over this forecast period. Owing to the higher demand for immediate therapeutic effects or critical care management and precise dosing control, the segment is accredited to drive the growth of the market in the coming years.
Based on the line of treatment, the global NAMPT inhibitor market is segregated into 1st Line and 2nd Line. According to market research, use of NAMPT inhibitors are 1st line therapy captures 97% of the market shares and this segment is projected to grow at a CAGR of 11% till 2040. As the NAMPT inhibitor continues to evolve and more drugs progress through clinical development, the 1st line of treatment is projected to propel the market demand during the forecast period.
This segment highlights the distribution of the market across various geographies, such as North America, Europe, Asia-Pacific, Latin America, Middle East, and North Africa. As per our analysis, North America accounts for 67% of the NAMPT inhibitor market share and is poised to fuel the market growth at a CAGR of 12% till 2040.
The “NAMPT Inhibitor Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in development of NAMPT inhibitors. The market report highlights the efforts of several manufacturers of small molecules and biologics in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the market size, competitive landscape, and geographical regions are briefly discussed below.
The market for NAMPT inhibitors witnessed a downturn during the unprecedented COVID-19 pandemic. The limitations on business industries including chemical, manufacturing, and transportation disrupted the global supply chain. In addition, the pandemic also obstructed several clinical trials which caused delays, suspensions, or cancellations of many ongoing studies, including those involving NAMPT inhibitors. Therefore, the NAMPT inhibitors market faced a slow down in the growth throughout this health emergency. However, the pandemic underscored the significance of immunotherapy in combating infectious diseases and stimulating the immune system's response. As a result, post-pandemic, the market started to recover from the previous years’ deficit and is expected to rise at a steady growth rate in the coming years.
The NAMPT inhibitor market is highly competitive and is expected to continue to evolve with the leading market players and the entering newcomer pharmaceutical companies in the global pharmaceutical industry. Numerous manufacturers, biopharmaceutical companies, and key stakeholders focus on drug development with continued research and clinical trials in oncology and metabolic diseases with the commercialization of NAMPT inhibitor drugs to offer novel treatment options for cancer and metabolic diseases.
The top three market players capture high market shares. For instance, OncoTartis currently holds 59% of the market share.
The trend of precision medicine and combination therapy is gaining traction and showing a strategic shift towards personalized treatment approaches and improved therapeutic results. Precision medicine's purpose is to tailor treatment to individual patients based on their unique genetic, molecular, and clinical characteristics. In the context of NAMPT inhibitors, researchers are progressively focused on identifying predictive biomarkers and genetic signatures that can inform treatment selection and optimize patient responses. This growing emphasis on precision medicine not only enhances treatment efficacy but also minimizes adverse effects by matching patients with the most appropriate therapies. As the field of precision medicine and combination therapy continues to advance, the NAMPT inhibitor market is poised to witness extensive growth with the market expansion, extending new opportunities for innovation and therapeutic breakthroughs.
In North America, the U.S. with 67% of the market share, is at the forefront of clinical research and drug development. Also, the U.S.’s robust biopharmaceutical industry and well-established research institutions significantly contribute to the region’s leading position. Additionally, the continuous research and development in the NAMPT inhibitors field, and the existence of prominent pharmaceutical companies, biotechnology firms, and academic research centers foster market growth. Consequently, these factors are expected to retain the region’s dominance throughout this forecast period.
Additionally, Asia Pacific is expected to grow at a substantial CAGR over this projection period. Primarily China and Japan are emerging as the biggest regions in the global pharmaceutical industry. Moreover, expanding healthcare expenditure, escalating focus on R&D, and the rising number of cancer cases can be the key factors behind the growth of the NAMPT inhibitor industry in the Asia Pacific.
By following the trend of the growing demand for more effective and versatile therapies, researchers in the field of NAMPT inhibitors are actively pursuing the development of next-generation inhibitors. These novel compounds are designed to overcome existing limitations by enhancing efficacy, selectivity, and pharmacokinetic properties. One approach involved the design of small molecule inhibitors with improved binding affinity and specificity for the NAMPT enzyme which allows greater therapeutic efficacy and reduced off-target effects. Additionally, researchers in the NAMPT inhibitors market are exploring alternative therapeutic modalities such as antibody drug conjugate and targeted protein degradation including PROTACs (proteolysis-targeting chimeras), which provide unique mechanisms of action and the potential for enhanced cancer targeting and drug delivery. By harnessing cutting-edge drug design and delivery technologies, next-generation NAMPT inhibitors hold the promise of revolutionizing cancer treatment and addressing unmet medical needs in oncology and beyond.
Examples of key companies engaged in the NAMPT inhibitor industry (which have also been profiled in this market report; the complete list of companies is available in the full report) include Antengene Therapeutics, Aqualung Therapeutics, Karyopharm Therapeutics, OncoTartis and Onxeo. This market report includes an easily searchable excel database of all the companies who are developing NAMPT inhibitors.
 |
 |
 |
 |
 |
 |
In the past few years, the market for NAMPT inhibitors has been blooming. Several ongoing innovations and developments are projected to boost market potential. These developments, even if they took place post the release of our market report, substantiate the overall trends that have been outlined in our NAMPT inhibitor market analysis.